Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06426979
Status:
COMPLETED
Last Update Posted:
2024-05-28
First Post:
2024-05-19
Brief Title:
Sequential Letrozole and Methotrexate Therapy Role in Treatment of Tubal Ectopic Pregnancy
Sponsor:
Zagazig University
Organization:
Zagazig University
Study Overview
Official Title:
Sequential Letrozole and Methotrexate Therapy Safely Improved the Outcomes of Medical Treatment of Tubal Ectopic Pregnancy
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ectopic pregnancy EP is a common condition involving the implantation of fertilized ovum outside the uterine cavity accounting for 1-2 of all pregnancies Tubal EP TEP is the most common and poses a significant risk to maternal life Early diagnosis and medical treatment such as methotrexate MTX and the Fallopian tube FT have been studied However the efficacy of single-dose methotrexate SD-MTX is questionable and the efficacy of two-dose versus SD-MTX for medical management of EP is being evaluated High estrogensprogesterone ratios can disrupt embryonic motility and lead to TEP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None